Sign in Subscribe

crc-research

A collection of 715 issues

Study explores caregiving experiences and support needs in Kazakhstan

Skip to content The CRC Digest ♥ LIVING WITH CRC Study explores caregiving experiences and support needs in Kazakhstan A qualitative study of 21 family caregivers in Kazakhstan examined caregiving experiences, burden, supportive care needs, and coping strategies among those caring for patients with colorectal cancer. (Nursing Reports) This content is

Australian audit finds gaps in surveillance colonoscopy guideline adherence

Skip to content The CRC Digest ▪ SCREENING Australian audit finds gaps in surveillance colonoscopy guideline adherence A clinical audit of six Victorian public hospitals assessed concordance of endoscopist-recommended surveillance colonoscopy intervals with 2018 Australian Cancer Council guidelines, identifying opportunities to improve adherence. (Australian Health Review) This content is informational only

CEMIP identified as candidate biomarker in early-onset colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH CEMIP identified as candidate biomarker in early-onset colorectal cancer Researchers identified CEMIP as elevated in colorectal cancer diagnosed before age 50 and associated with poorer overall survival, with evidence linking it to PTCH1-related Hedgehog signaling pathways. (Genes) This content is informational only and

Ifebemtinib plus garsorasib shows antitumor activity in KRAS G12C metastatic colorectal cancer

Skip to content The CRC Digest ▸ TREATMENT Ifebemtinib plus garsorasib shows antitumor activity in KRAS G12C metastatic colorectal cancer A combination of ifebemtinib and garsorasib demonstrated encouraging antitumor activity in previously treated metastatic colorectal cancer patients with KRAS G12C mutations, according to results published in The Lancet Oncology. (The Manila

Targeted m6A Demethylation of ZBTB7A Suppresses Liver Metastasis in Preclinical Models

Skip to content The CRC Digest Targeted m6A Demethylation of ZBTB7A Suppresses Liver Metastasis in Preclinical Models Researchers identified ZBTB7A as an m6A-modified transcription factor that promotes colorectal cancer liver metastasis, with METTL3-mediated m6A modification of ZBTB7A facilitating recognition by the m6A reader YTHDF1/3 complex. (Molecular Cancer) This content

Real-World Study Characterizes Colorectal Neoplasia in Adults Under 50

Skip to content The CRC Digest Real-World Study Characterizes Colorectal Neoplasia in Adults Under 50 A single-center study of 152 patients aged 18-49 who underwent colonoscopy between 2018 and 2023 characterized the clinical, anatomical, and histopathological features of colorectal lesions in younger adults. (Journal of Clinical Medicine) This content is

Fusobacterium nucleatum Detected in 11% of Adenomas, Linked to Immune Signatures

Skip to content The CRC Digest ◇ RESEARCH Fusobacterium nucleatum Detected in 11% of Adenomas, Linked to Immune Signatures RNA-based detection found Fusobacterium nucleatum in 11% of adenoma tissue samples, with positive patients exhibiting enriched anti-bacterial defense response and immune-related transcriptomic signatures compared to negative patients. (International Journal of Molecular Sciences)

Genetic Risk Stratification Identifies High Adenoma Detection Rates at Colonoscopy

Skip to content The CRC Digest ▪ SCREENING Genetic Risk Stratification Identifies High Adenoma Detection Rates at Colonoscopy A retrospective study of 800 adults from a US health-system biobank who underwent colonoscopy between 2010 and 2025 found that inherited genetic risk may improve yield of adenoma detection and prioritization of colonoscopy

Blood Test Combining cfDNA Fragmentomics and Methylation Markers Detects Precancerous Lesions

Skip to content The CRC Digest ▪ SCREENING Blood Test Combining cfDNA Fragmentomics and Methylation Markers Detects Precancerous Lesions A study of 380 CRC patients, 121 individuals with precancerous lesions, and 506 healthy controls found that adding methylation analysis of SEPT9 and HS3ST2 to cfDNA fragmentomic features improved detection of precancerous

Final Analysis of DEEPER Trial Shows No Survival Difference Between Cetuximab and Bevacizumab in RAS/BRAF Wild-Type mCRC

Skip to content The CRC Digest ◆ TRIAL DATA Final Analysis of DEEPER Trial Shows No Survival Difference Between Cetuximab and Bevacizumab in RAS/BRAF Wild-Type mCRC The phase II DEEPER trial found no differences in progression-free survival or overall survival in the per-protocol set when comparing modified-FOLFOXIRI plus cetuximab versus